Navigation Links
Phase III data show investigational compound empagliflozin significantly reduced blood glucose in adults with type 2 diabetes
Date:6/22/2013

h therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim has a demonstrated commitment to corporate social responsibility. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.

In 2012, Boehringer Ingelheim achieved net sales of about $19.1 billion (14.7 billion euro). R&D expenditure in the business area Prescription Medicines corresponds to 22.5 percent of its net sales.
For more information please visit www.us.boehringer-ingelheim.com

About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, IN, Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.

About Lilly Diabetes
Lilly has been a global leader in diabetes care since 1923, when we introduced the world's first commercial insulin. Today we work to meet the diverse needs of people with diabetes through research and collaboration, a broad and growing product portfolio and a continued commitment to providing real solutions – from medicines to support programs and more – to make lives better.

For more information, visit www.lillydiabetes.com.

P-LLY
DIA568014PR

This press release cont
'/>"/>

SOURCE Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Follow-up Phase II Data Analysis Adds to Body of Evidence for Investigational Novel Basal Insulin, LY2605541
2. Phase III data show significant reduction in blood glucose with investigational compound empagliflozin added to metformin or metformin plus sulfonylurea in adults with type 2 diabetes
3. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
4. Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine
5. Safinamide Phase III Study Results Presented at 2013 MDS Meeting
6. Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinsons Disease
7. Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
8. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
9. Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
10. Ibrutinib Phase 2 Data: Analyses Show Efficacy with Ibrutinib Monotherapy in Patients with Relapsed or Refractory Mantle Cell or Diffuse Large B-cell Lymphoma
11. Lilly Voluntarily Terminates Phase II Study for LY2886721, a Beta Secretase Inhibitor, Being Investigated as a Treatment for Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
(Date:1/14/2014)... , Jan. 14, 2014 HeartWare International, Inc ... of less invasive, miniaturized circulatory support technologies that are ... that it expects revenues for the fourth quarter of ... 2013 revenues to approximately $208 million. "Our ...
(Date:1/14/2014)... North America,s leading business partnering event ... 30 th edition of its annual conference at the ... 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... specialty chemical companies will take part in the conference, which ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... Global public relations leader Porter Novelli today announced that ... Prix Galien USA Awards, which recognize excellence in biopharmaceutical ... condition. Porter Novelli will be responsible for raising awareness ... of submissions. The Prix Galien is ...
...   - Jayex , ... the Trust to , Instantly Review ... , Delivery of High-Quality Patient,Centred Care ... technology specialist, http://www.jaxex.com today,announces that United Lincolnshire NHS Trust (ULHT) has,selected ...
Cached Medicine Technology:Porter Novelli Named Agency of Record for Prix Galien USA Awards 2United Lincolnshire Hospitals NHS Trust Selects Jayex QI Interactive Patient Survey and Information Management Kiosk 2
(Date:4/23/2014)... J. O,Shea, M.D., scientific director at the National Institute ... been named the 2014 recipient of the Ross Prize ... open-access journal Molecular Medicine . The award will ... Academy of Sciences in Manhattan, followed by scientific presentations ... part of the National Institutes of Health. , The ...
(Date:4/23/2014)... The American Society for Radiation Oncology (ASTRO) has ... Radiation Therapy for Endometrial Cancer: An ASTRO Evidence-Based ... therapy in the treatment of endometrial cancer. The ... 2014 issue of Practical Radiation Oncology ... The full-length guideline is available as an open-access ...
(Date:4/23/2014)... Ind. - Purdue University researchers have developed a way ... cell by using tiny gold particles with tails of ... of agricultural and biological engineering, used gold nanoparticles to ... as BRCA1 messenger RNA splice variants, which can indicate ... of these mRNA splice variants in a cell can ...
(Date:4/23/2014)... compound that targets an important brain receptor has a ... including relapse behavior, a University at Buffalo animal study ... this may be a novel lead compound for treating ... UB research was published as an online preview article ... study, the compound, RO5263397, severely blunted a broad range ...
(Date:4/23/2014)... 2014Men whose testosterone falls below normal levels are more ... and have heart disease and type 2 diabetes. A ... for further testing and possible treatment is described in ... a peer-reviewed publication from Mary Ann Liebert, Inc., publishers. ... of Men,s Health website at http://www.liebertpub.com/jmh . ...
Breaking Medicine News(10 mins):Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2Health News:Novel compound halts cocaine addiction and relapse behaviors 2
... A leading authority on the aging, health and retirement of ... the ability of Americans to provide for the long term ... November 12, Dr. Dychtwald will address members of the news ... importance of long term care planning. This topic is ...
... , PHILADELPHIA, Oct. 28 Health Partners announced ... the state Children,s Health Insurance Program (CHIP). CHIP, brought ... already begun enrolling members in Philadelphia County and will ... , CHIP offers quality health insurance to all uninsured ...
... Oct. 28 Carefx Corporation , ... and safety of patient care, is listed among the " ... by IDC, a leading IT market research and advisory firm. ... Oct. 26, profiles companies "with the vision and technology to have ...
... a subsidiary of Eisai Inc., announced today that it ... Biotech Inc. for development and commercialization of an antibody ... tumors. , Under the terms of the ... for the development, manufacture and sale of the antibody. ...
... Health Foundation today announced that it has awarded The ... to create education and outreach programs that empower pharmacists, ... misuse in their communities. , According to the Ohio ... Ohio high school students have reported using a prescription ...
... LONDON, October 28 Even though no-one wants to ... to look good at the,ubiquitous Christmas Party then follow the realbuzz.com guide ... diet and healthy living go out,the window, so now,s the time to ... - we wouldn,t be realbuzz.com if we didn,t offer this piece of,advice ...
Cached Medicine News:Health News:Dr. Ken Dychtwald to Discuss Looming 'Caregiver Crunch' and the Importance of Proactive Long Term Care Planning 2Health News:Health Partners to Offer Health Insurance Through the Children's Health Insurance Program 2Health News:Carefx Named an Innovative Information Access 'Company to Watch' By Leading Market Research Firm 2Health News:Carefx Named an Innovative Information Access 'Company to Watch' By Leading Market Research Firm 3Health News:Morphotek(R), Inc. Announces a Licensing Deal With Centocor Ortho Biotech Inc. for Exclusive Development and Commercialization Rights for a Therapeutic Monoclonal Antibody 2Health News:Cardinal Health Foundation, The Ohio State University College of Pharmacy Join Forces to Prevent Prescription Medication Abuse 2Health News:The Countdown to Christmas - The realbuzz.com Guide to a Healthier You! 2
... a vacuum tube for the collection, transport ... immunophenotyping by flow cytometry. The preservative contained ... the white blood cell cluster of differentiation ... Patient samples collected in Cyto-Chex BCT are ...
Streck-ONYX-Pack is specially designed for use on Coulter® ONYX Series instruments. Each pack contains diluent and lysing agent. The shelf life is one year from date of manufacture....
... reagent manufactured for the simultaneous quantitative ... cells. Streck-Lysing Agent IIIC is for ... S Plus II, III, IV, V, ... JT Series. The shelf life is ...
Streck-CD3500 Hemoglobin/Lyse is a lytic reagent for the quantitative determination of hemoglobin on the Abbott CELL-DYN® 3500 and 3700. The shelf life is two years from the date of manufacture....
Medicine Products: